Context Interest in the role of fibrates intensified after the publication of the negative results
from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which assessed
therapy with fenofibrate plus statins. The evidence for clinical benefit in outcomes with the
use of fibrates is heavily weighted on the use of the older fibrates such as gemfibrozil and
clofibrate. Objectives To examine trends in the current use of fibrates and to examine the
relationship between differences in the availability and use of brand-name vs generic …